Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in AustraliaPharmacoeconomicsIF4.62022-06-270OAAI
Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluationHEALTH TECHNOLOGY ASSESSMENTIF42021-02-018OA
BENRALIZUMAB FOR TREATING SEVERE EOSINOPHILIC ASTHMA: NICE SINGLE TECHNOLOGY APPRAISALVALUE IN HEALTHIF62019-05-012OAAI
Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation帮助诊断早产的三种生物标志物测试: 系统评价和经济评估HEALTH TECHNOLOGY ASSESSMENTIF42019-03-015OA
BIOMARKER TESTS TO HELP DIAGNOSE PRETERM LABOUR IN SYMPTOMATIC WOMEN WITH INTACT MEMBRANES: A SYSTEMATIC REVIEWJOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTHIF3.72018-09-050OAAI
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysisHEALTH TECHNOLOGY ASSESSMENTIF42018-09-0123OA
EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and UncertaintiesAPPLIED HEALTH ECONOMICS AND HEALTH POLICYIF3.32018-05-2812OAAI
AZACITIDINE FOR TREATING ACUTE MYELOID LEUKAEMIA: A NICE SINGLE TECHNOLOGY APPRAISALVALUE IN HEALTHIF62016-11-010OAAI
Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic modelHEALTH TECHNOLOGY ASSESSMENTIF42016-08-0147OA
COST EFFECTIVENESS OF CETUXIMAB AND PANITUMUMAB FOR FIRST-LINE RAS WT METASTATIC COLORECAL CANCERVALUE IN HEALTHIF62016-05-011OAAI
The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic modelHEALTH TECHNOLOGY ASSESSMENTIF42016-02-018OA
A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patientsBMC CANCERIF3.42015-04-2535OAAI
MODEL-BASED COST-UTILITY ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR THE TREATMENT OF CANCER-TREATMENT INDUCED ANAEMIA IN THE UK NHSVALUE IN HEALTHIF62014-11-011OAAI
WHEN IT MAY NOT BE NECESSARY TO MODEL OVERALL SURVIVAL FOR ECONOMIC EVALUATIONS OF ANTI-CANCER DRUGSVALUE IN HEALTHIF62014-11-010OAAI
A systematic review and economic evaluation of diagnostic strategies for Lynch syndromeHEALTH TECHNOLOGY ASSESSMENTIF42014-09-01122OA
COST-EFFECTIVENESS OF SYSTEMATIC TESTING FOR LYNCH SYNDROME IN PATIENTS NEWLY DIAGNOSED WITH COLORECTAL CANCER IN THE UNITED KINGDOMVALUE IN HEALTHIF62013-11-010OAAI
Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancerBRITISH JOURNAL OF CANCERIF6.82013-09-1736OAAI
Complete Cytogenetic Response and Major Molecular Response as Surrogate Outcomes for Overall Survival in First-Line Treatment of Chronic Myelogenous Leukemia: A Case Study for Technology Appraisal on the Basis of Surrogate Outcomes EvidenceVALUE IN HEALTHIF62013-09-0121OAAI